Search consultations


Proposal to fund treatments for cancer and asthma

NZNO invites you to provide feedback on PHARMAC’s proposal to fund new treatments for lung cancer and severe refractory eosinophilic asthma, as well as widen access to a treatment for ovarian cancer.

The agreement with AstraZeneca would also include amendments to the contractual arrangements for budesonide with eformoterol powder for inhalation (Symbicort Turbuhaler), fulvestrant (Faslodex) and gefitinib (Iressa).

Please refer here for further information about the proposed changes.

Please send feedback to by 24 January 2022.

Notify me when this page changes

Enter your email address below to receive alerts when this page is updated.

Sign up below to receive an email when we update this page

Enter the code shown above in the box below.